Transaction · 0001636282-26-000069

Fairmount Funds Management LLC

Fairmount Funds Management LLC, DIR, reported a transaction classified as grant at Spyre Therapeutics, Inc. involving 8026.000000 shares for an estimated $0.00. Reported holdings after the transaction were 8026.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
SYRESpyre Therapeutics, Inc.
Trade date
May 27, 2026
Filing date
May 29, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded8.02k$0.00 per share
Holdings after8.02kIndirect · By Tomas Kiselak
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

SYRE price since this filing

Daily closing prices, with the filing date and available return windows
SYRE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -2.2%1w ago -2.1%1d ago +0.2%
Returns since7d +0.2%30d +19.6%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001636282-26-000069
Stock Option (Right to Buy)
Transaction date
May 27, 2026
Filed May 29, 2026, 09:58 PM · 2d delay
Shares
8,026 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
8,026 sh
Indirect · By Tomas Kiselak

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 ann…

  2. F2

    Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund").…

Original filing · 0001636282-26-000069
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

SYRE